Plastic and Reconstructive Surgery • February 2019 situ decompression, subcutaneous transposition, submuscular transposition, and medial epicondylectomy. Multiple randomized trials, [6] [7] [8] [9] and a meta-analysis of randomized controlled trials, 10 have failed to show a difference in clinical outcomes between these methods even in the setting of severe neurologic impairment. Additional meta-analyses failed to demonstrate differences in clinical outcome scores or improvements in motor conduction velocities for patients undergoing in situ decompression and anterior transposition of the ulnar nerve, 11 or differences in outcomes between open and endoscopic techniques. 12, 13 Therefore, none of these procedures have demonstrated superiority, and it remains unclear whether revision rates differ between these techniques.
Although substantial efforts have been made to compare the clinical outcomes for various cubital tunnel syndrome surgical treatments, [6] [7] [8] [9] 11, [14] [15] [16] [17] [18] there is a paucity of studies attempting to understand cost differences between these methods. In 2007, Brauer and Graham published a decision analysis to compare in situ decompression, subcutaneous transposition, submuscular transposition, and medial epicondylectomy. 19 In situ decompression demonstrated the highest expected utility, and the authors supported this as the preferred surgical strategy for cubital tunnel syndrome based on their results. Subsequently, in 2012, Song et al. published a cost-utility analysis using Medicare estimated payment data to compare four treatment strategies: (1) in situ decompression followed by salvage submuscular transposition, (2) subcutaneous transposition followed by salvage submuscular transposition, (3) medial epicondylectomy followed by salvage submuscular transposition, and (4) submuscular transposition as the index procedure. 20 The authors concluded that in situ decompression was a cost-effective treatment for cubital tunnel syndrome, with effectiveness ratios of less than $2027 per quality-adjusted lifeyear. Despite these informative studies, surgical encounter total direct costs associated with surgical treatments for cubital tunnel syndrome still currently lack transparency. Given similar clinical outcomes reported in the peer-reviewed literature for in situ decompression, subcutaneous transposition, and submuscular transposition, the discussion related to what constitutes appropriate treatment should also focus on improving value through cost reduction in addition to the prior focus on clinical factors when choosing the treatment technique. 18, [21] [22] [23] Our institution has developed a value-driven outcomes database containing detailed patientand item-level total direct cost and payment data for a variety of health care services. This validated tool has successfully identified areas of high variability in cost, leading to improved value of care delivered. 1, 24, 25 In the current study, the valuedriven outcomes tool was used to test the primary null hypothesis that surgical encounter total direct surgical costs were no different for in situ decompression, subcutaneous transposition, and submuscular transposition.
PATIENTS AND METHODS
This institutional review board-approved retrospective study considered for inclusion all adult (≥18 years of age) patients undergoing surgical treatment for cubital tunnel syndrome between August of 2011 and December of 2016 performed by four fellowship-trained orthopedic hand surgeons at a single tertiary academic institution. Patients were identified by CPT code (64718). Manual chart review was performed to determine whether open in situ decompression, subcutaneous transposition, or submuscular transposition was performed, and to collect corresponding basic demographic and surgical data. Manual chart review of all operative, anesthesia, and orthopedic clinic notes was performed to confirm that the diagnosis of cubital tunnel syndrome had been established, to record the anesthesia type, and to exclude patients undergoing additional simultaneous procedures including other operations or injections, those with prior injury (fracture and/or dislocation) or surgery to the elbow, and those undergoing revision decompression. Also excluded were patients treated surgically before August of 2011 (corresponding with initiation of the value-driven outcomes database at our institution).
In situ decompression, subcutaneous transposition, and submuscular transposition were performed as described previously. 26 Based on surgeon preferences, subcutaneous transposition was performed using a flexor-pronator fascial sling, or by suturing subcutaneous tissue from the anterior skin flap to the medial epicondyle, to prevent posterior translation of the ulnar nerve. Submuscular transposition was performed using a Z-cut in the flexor-pronator fascia and excision of muscular septae, which was repaired following transposition. Nerve tubes, nerve wraps, or other similar adjuncts were not used in any case. Operations were performed under monitored anesthesia care with local or general anesthesia or under a surgical block with monitored anesthesia care based on surgeon preference.
Surgical encounter total direct cost data were collected from the value-driven outcomes database for each individual surgery performed. The value-driven outcomes information technology tool draws prospectively collected payment data and patient-and item-level total direct cost data from our institution's data warehouse for specific patient encounters. Value-driven outcomes costing methods have been described previously, yielding total direct costs for materials used for patient care, facility use direct costs (including sterile processing costs), and time-based cost allocations including procedure/operative time and cost of staff involved in care (e.g., nursing, surgical technicians, medical assistants). 1, 24, 25 Specific cost categories are further elucidated. (See Appendix, Supplemental Digital Content 1, which shows the breakdown of value-driven outcomes database categories for total direct costs, http://links.lww.com/PRS/D259.) All reported cost data were normalized using each individual's cost divided by the median cost in the data set, to comply with institutional guidelines prohibiting the public reporting of raw financial data related to the details of non-publically disclosed contractual agreements.
Continuous variables were summarized as mean and standard deviation, and categorical variables were summarized as number and percentage. Raw cost data were converted to January of 2016 U.S. dollars using the consumer price index, based on the month and year of the operation. 27 Relative costs were then calculated by normalizing each distinct group mean by the lowest group median. Surgical encounter total direct surgical costs were compared among in situ decompression, subcutaneous transposition, and submuscular transposition using the KruskalWallis test with Tukey pairwise comparisons. Univariate and multivariable gamma regression with a log link was used to model surgical encounter total direct surgical costs. Based on clinical practice patterns, in situ decompression is more likely to be performed under monitored anesthesia care than transpositions at our institution, and transpositions were more likely to be performed under general or surgical block than in situ decompression. Because of this direct clinical association between anesthesia type and surgical method, the primary multivariable regression analysis did not include anesthesia type as a predictor. However, because of potential influences of anesthesia type on surgical encounter total direct surgical costs, a secondary multivariable regression analysis was performed that included anesthesia type as a predictor to determine whether costs of in situ decompression differed from transposition (subcutaneous transposition and submuscular transposition).
Age was compared among in situ decompression, subcutaneous transposition, and submuscular transposition groups using one-way analysis of variance with the Tukey honestly significant difference test for multiple comparisons. Surgical times were compared using rhe Kruskal-Wallis test followed by pairwise Wilcox rank sum tests with a Bonferroni correction for multiple comparisons. Categorical variables were compared using the Fisher's exact test or chi-square test with pairwise tests using a Bonferroni correction. Statistical significance was assessed at the 0.05 level, and all applicable tests were two-tailed.
An a priori power analysis was performed. To detect a medium effect size of 0.5 in standard deviation units between in situ decompression and subcutaneous transposition groups, 80 percent power would be achieved to detect statistical significance at a two-tailed 0.05 alpha level with 64 patients per group. With 45 patients in the in situ decompression group and 62 patients in the subcutaneous transposition group, we had 80 percent power to detect an effect size of 0.55 between these two groups.
RESULTS
Of 158 surgical encounters identified by CPT code, 37 were excluded (24 revisions, nine with prior elbow surgery, and four with additional simultaneous procedures). Two patients underwent staged bilateral in situ decompression, seven underwent staged bilateral subcutaneous transposition, and one underwent staged in situ decompression followed by contralateral subcutaneous transposition. Therefore, in total, 45, 62, and 14 unique surgical encounters for in situ decompression, subcutaneous transposition, and submuscular transposition, respectively, were included.
Baseline patient characteristics and surgical details are listed in Table 1 . Mean age was 52.2, 41.3, and 48.1 years, respectively (p < 0.05 between in situ decompression and subcutaneous transposition). There were no differences in sex or body mass index between groups. Mean surgical times were 28.0, 46.5, and 50.0 minutes, respectively. Surgical time for in situ decompression was Plastic and Reconstructive Surgery • February 2019 significantly less than for subcutaneous transposition or submuscular transposition (p < 0.05), with no difference between subcutaneous transposition and submuscular transposition (p > 0.05 per pairwise Wilcoxon rank sum tests with a Bonferroni correction for multiple comparisons).
Surgical encounter total direct surgical costs differed significantly between surgical methods (p < 0.05) (Fig. 1) . Facility use costs constituted the majority of surgical encounter total direct surgical costs for in situ decompression, subcutaneous transposition, and submuscular transposition (71, 74, and 67 percent, respectively), and were significantly greater (1.4-and 1.6-fold) for subcutaneous transposition and submuscular transposition, respectively, compared with in situ decompression. Facility costs were greater for subcutaneous transposition than for in situ decompression (p < 0.05), greater for submuscular transposition than for in situ decompression (p < 0.05), but not different between subcutaneous transposition and submuscular transposition (p > 0.05 per pairwise Wilcoxon rank sum tests with a Bonferroni adjustment for the multiple comparisons). Recovery room costs were the second largest contributor to surgical encounter total direct surgical costs for in situ decompression, subcutaneous transposition, and submuscular transposition (15, 16 , and 15 percent, respectively), and were significantly greater by 1.3-and 1.6-fold for subcutaneous transposition and submuscular transposition, respectively, compared with in situ decompression. Recovery room costs for in situ decompression were significantly less than for submuscular transposition (p < 0.05), with no other differences between groups (p > 0.05). Pharmacy costs were the third largest contributor to surgical encounter total direct surgical costs for in situ decompression, subcutaneous transposition, and submuscular transposition (9, 10, and 6 percent, respectively), and were significantly greater by 1.5-and 1.2-fold for subcutaneous transposition and submuscular transposition, respectively, compared with in situ decompression. Pharmacy costs for in situ decompression were significantly less than for subcutaneous transposition (p < 0.05), with no other differences between groups (p > 0.05). Univariate gamma regression revealed that surgical method and provider contributed significantly to surgical encounter total direct surgical costs, and suggested nonsignificance of factors including age, sex, body mass index, and American Society of Anesthesiologists class ( Table 2 ). The primary multivariable gamma regression analysis found that subcutaneous transposition was 1.18-fold more costly than in situ decompression (p < 0.05), and submuscular transposition was 1.55-fold more costly than in situ decompression (p < 0.05) while controlling for age, sex, and provider (Table 3 ). The secondary multivariable gamma regression analysis found that transposition was 1.18-fold more costly than in situ decompression (p < 0.05) when adding anesthesia type to the primary multivariable regression model, and suggested that general anesthesia is 31 percent more expensive than monitored anesthesia care (p < 0.05) while controlling for age, sex, and provider (Table 4 ). Power analysis revealed that with 45 patients in the in situ decompression group and 62 patients in the subcutaneous transposition group, 80 percent power was achieved at a two-tailed 0.05 alpha level to detect an effect size of 0.55 between these two groups.
DISCUSSION
Our main finding was that surgical encounter total direct costs for subcutaneous transposition and submuscular transposition were significantly greater than for in situ decompression by 1.18-and 1.55-fold, respectively. These differences were associated with discrepancies in facility costs, recovery room costs, and pharmacy costs. Therefore, we rejected our null hypothesis.
Although we were unable to identify a study reporting actual direct costs for these surgical procedures, our findings add strength to the current literature. Song et al. performed a cost-utility analysis evaluating four treatment strategies for cubital tunnel syndrome surgical treatment: (1) in situ decompression followed by salvage submuscular transposition, (2) subcutaneous transposition followed by salvage submuscular transposition, (3) medial epicondylectomy followed by salvage submuscular transposition, and (4) submuscular transposition as the index procedure. 20 Estimated costs derived from Medicare reimbursement rates, rather than actual direct costs, were used as a surrogate for cost. Given the database study design and identical CPT coding for in situ decompression, subcutaneous transposition, and submuscular transposition (CPT code 64718), the study was limited in the ability to accurately estimate surgical direct costs for these three procedures: direct costs related to surgical services; anesthesia services; and facility fees were assumed to be identical for in situ decompression, subcutaneous transposition, and submuscular transposition in their study. This 
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contrasts with our observed significant differences in surgical costs among the three procedures. However, strengths of their study include estimation of indirect and opportunity costs related to missed work and recovery, and by performing a full cost-utility analysis from a societal perspective based on a comprehensive review of complication rates in the literature. Nonetheless, the authors concluded that initial surgical treatment with in situ decompression was more cost-effective than proceeding first with subcutaneous transposition, submuscular transposition, or medial epicondylectomy. These conclusions mirror those of the decision analysis study published by Brauer and Graham. 19 We speculate that the calculated costeffectiveness of in situ decompression would be even more favorable if the model were run using the actual surgical encounter total direct surgical costs of the current study.
Limitations of the current study deserve mention. Although each surgical procedure was verified with chart review, the initial identification of patients by procedure code, the retrospective study design, and evaluation of patients from a 
. For example, a value of 1.6 is interpreted as a 60% increase in total direct costs as compared to the reference category. †Per additional 1 yr of age. ‡Note that anesthesia type and surgical method are confounded because of clinical practice patterns, ISD is more likely to be performed under MAC, and transpositions are more likely to be performed under general anesthesia. §Statistically significant. 
. For example, a value of 1.6 is interpreted as a 60% increase in total direct costs as compared to the reference category. †Note that anesthesia type and surgical methods are associated because of clinical practice patterns in which ISD is more likely to be performed under monitored anesthesia care, and transpositions are more likely to be performed under general anesthesia. By including both predictors, the effect of surgical method may be falsely lowered.
‡Per additional 1 yr of age. §Statistically significant.
single center introduce potential for selection bias. Because of the nonrandomized study design, significant differences in age, American Society of Anesthesiologists class, and anesthesia type were observed between some of the groups. However, it is unclear whether these differences would affect surgical costs. Generalizability of our results may be limited by our unique pricing agreements between our institution and suppliers, which may affect total direct costs of time-allocated costs of operating room time, perioperative services, and other products used during the surgical encounter. We acknowledge that medial epicondylectomy and endoscopic in situ decompression are described options for cubital tunnel syndrome, 28, 29 and our study is limited given that none of the surgeons at our institution performs these procedures. We did not quantify the opportunity cost for in situ decompression versus transpositions in which the latter required more surgical time, nor does the value-driven outcomes database include indirect cost data such as those related to housekeeping, electricity, or property rent/depreciation. Our study is not a true cost-effectiveness analysis, as we did not combine our cost findings with outcomes; however, historically, no cubital tunnel syndrome surgical procedure has been shown to lead to superior outcomes. [7] [8] [9] 11, 14, 30 In addition, anesthesia type and surgical method are associated. Because of clinical practice patterns at our institution, in situ decompression is more likely to be performed under monitored anesthesia care, and transpositions are more likely to be performed under general anesthesia. Although it is impossible to statistically dissect one from the other, and it is likely that our secondary multivariable analysis underestimates the impact of surgical technique on cost because of an association of surgical method and anesthesia type, our reporting methods for primary and secondary multivariable regression analyses both suggest that surgical method affects surgical encounter total direct surgical costs.
One additional limitation that deserves specific mention pertains to generalizability of our findings. Although the value-driven outcomes database has previously been validated and has successfully been used to improve value of care, 1, 24, 25 our results should be generalized with caution, as operating room staffing and recovery room protocols, the insurance payer mix, and negotiated rates for medications and surgical supplies may differ by region. We acknowledge that facility costs, recovery room costs, and costs of medications and supplies for cubital tunnel release surgical encounters likely differ at other institutions. Nonetheless, our observed differences in surgical encounter total direct surgical costs between in situ decompression and transpositions were driven mostly by facility costs, which are in turn driven by surgical time. At other institutions, surgical times may differ based on surgeon experience and whether trainees are involved, which could affect surgical encounter total direct surgical costs. Because costs likely differ for other institutions, our observed differences in relative costs between in situ decompression, subcutaneous transposition, and submuscular transposition may be more generalizable than the actual costs.
CONCLUSIONS
We found that surgical encounter total direct costs for subcutaneous transposition and submuscular transposition were 1.18-and 1.55-fold greater than in situ decompression. These differences were associated with differences in facility costs, recovery room costs, and pharmacy costs. In light of similar outcomes in the current literature for in situ decompression, subcutaneous transposition, and submuscular transposition, 11, 30 cost differences between these procedures should be considered when indicating cubital tunnel syndrome patients for surgery in addition to clinical factors such as prior elbow trauma, nerve mobility, symptom severity, 22, 23 and greater morbidity associated with transposition. 18 Awareness of cost implications for these surgical techniques may result in substantial savings over time. 
